Project description:Inflammatory immune disorders such as inflammatory bowel disease (IBD) and multiple sclerosis (MS) are major health problems. Currently, the intestinal whipworm Trichuris suis is being explored in clinical trials to reduce inflammation in these diseases, however, the mechanisms by which the parasite affects the host immune system are not known. Here we determined the effects of T. suis soluble products (SPs) on toll-like receptor-4 (TLR4)-stimulated human dendritic cells (DCs) using Illumina bead chip gene arrays. Pathway analysis of lipopolysaccharide (LPS)-stimulated DCs with or without T. suis treatment showed that costimulation with T. suis SPs resulted in a down-regulation of both the myeloid differentiation primary response gene 88 (MyD88)-dependent and the TIR-domain-containing adaptor-inducing interferon-β (TRIF)-dependent signalling pathways triggered by TLR4. These data were verified using quantitative real-time PCR of several key genes within these pathways and/or defining their protein levels. In addition, T. suis SPs induce Rab7b, a negative regulator of TLR4 signalling that interferes with its trafficking, which coincided with a reduced surface expression of TLR4. These data indicate that the mechanism by which T. suis SPs reduce inflammatory responses is through suppression of both TLR4 signalling and surface expression on DCs.
Project description:We describe the transcriptional changes occurring in lamina propria mononuclear cells (LPMC) and intestinal epithelial cells (IEC) upon Trichuris suis ova (TSO) treatment in a rabbit model of DSS colitis
Project description:We analysed the exosomes secreted by the nematode Trichuris muris. Two replicates of exosomes were analysed using a 5600+ mass spectrometer
Project description:The MUCUS clinical trial (https://clinicaltrials.gov: NCT01433471) was established to investigate the effect of Trichuris suis ova on ulcerative colitis patients.
